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Abstract
Background: Quality of life among prostate cancer survivors varies by socio-demographic factors and treatment
type received; however, less in known about differences in functional outcomes by method of presentation. We
investigate differences in reported urinary, bowel, sexual and hormone-related problems between symptomatic
and PSA-detected prostate cancer survivors.
Methods: A UK wide cross-sectional postal survey of prostate cancer survivors conducted 18-42 months post-
diagnosis. Questions were included on presentation method and treatment. Functional outcome was determined
using the EPIC-26 questionnaire. Reported outcomes were compared for symptomatic and PSA-detected survivors
using ANOVA and multivariable log-linear regression.
Results: Thirty-five thousand eight hundred twenty-three men responded (response rate: 60.8%). Of these, 31.3%
reported presenting via PSA test and 59.7% symptomatically. In multivariable analysis, symptomatic men reported
more difficulty with urinary incontinence (Adjusted mean ratio (AMR): 0.96, 95% CI: 0.96-0.97), urinary irritation (AMR:
0.95, 95% CI: 0.95-0.96), bowel function (AMR: 0.97, 95% CI: 0.97-0.98), sexual function (AMR: 0.90, 95% CI: 0.88-0.92),
and vitality/hormonal function (AMR: 0.96, 95% CI: 0.96-0.96) than PSA-detected men. Differences were consistent
across respondents of differing age, stage, Gleason score and treatment type.
Conclusion: Prostate cancer survivors presenting symptomatically report poorer functional outcomes than PSA-
detected survivors. Differences were not explained by socio-demographic or clinical factors. Clinicians should be aware
that men presenting with symptoms are more likely to report functional difficulties after prostate cancer treatment and
may need additional aftercare if these difficulties persist. Method of presentation should be considered as a covariate in
patient-reported outcome studies of prostate cancer.
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Background
Prostate cancer is the most commonly diagnosed cancer
among men from Western countries and the second
most common cancer among men worldwide [1, 2]. The
overwhelming majority of men diagnosed with prostate
cancer either present symptomatically to a clinician or
by a prostate specific antigen (PSA) test as part of a
general/private health check [3]. Controversy exists
regarding the PSA test as a screening test for prostate
cancer, with conflicting conclusions regarding the test’s
ability to lower prostate cancer related mortality [4–6].
In the absence of evidence of the benefits of PSA testing
all men aged 50 and over in the UK may have a PSA test
if they request it after being made aware of its potential
implications [7, 8]. In England approximately 9 out of
100 men have a PSA test each year (2010-2011, aged 45-
84), with only one quarter of these men having relevant
urinary symptoms in the 12months prior to the test [9].
Of the men having a PSA test for any reason 12% were
referred to secondary care within 14 days and 4% had a
diagnosis of prostate cancer [9]. Potential implications of
PSA-testing for asymptomatic prostate cancer include
the problem that 23-43% of these cancers are clinically
insignificant, while men with clinically significant disease
may be aware of their diagnosis for longer but with no
survival benefit [10, 11]. Regardless of these issues all
men diagnosed with both PSA-detected and symptom-
atic prostate cancer have to decide upon monitoring or a
course of treatment, the latter of which can be associ-
ated with side effects [12–16].
Previous research found asymptomatic men diagnosed
by PSA testing were younger, more affluent, had fewer
comorbidities, earlier stage disease, lower Gleason score,
and were more likely to have radical prostatectomy or
brachytherapy/radiotherapy compared with symptomatic-
ally diagnosed men [17–19]. Although the characteristics
of PSA-detected men are well documented, investigations
of differences in outcomes between PSA-detected and
symptomatic men are limited. Previous studies found
PSA-detected men have better progression free survival
after radical prostatecomy [19] lower disease specific mor-
tality [20], reduced risk of metastases [20] and report
better psychological wellbeing [17] compared to symp-
tomatically diagnosed men after adjustment for stage and
treatment. Although urinary incontinence, impotence,
bowel problems and fatigue were also found to be more
common among symptomatic men, these differences were
unadjusted for treatment or stage [17].
In this study differences in prostate cancer related func-
tional outcomes between symptomatic and PSA-detected
survivors are investigated as part of the Life After Prostate
Cancer Diagnosis (LAPCD) study [21], a population based
study of over 35,000 men diagnosed with prostate cancer
18-42months previously, the results of which have been
previously reported for specific stage and treatment types
[12]. In addition, for the first time, we investigate whether
differences in functional outcomes between symptomatic
and PSA-detected survivors can be explained by socio-
demographic or clinical characteristics, and thus provide
an assessment of the degree to which method of presenta-




Fifty-eight thousand nine hundred thirty men living with a
prostate cancer diagnosis in the previous 18-42months were
surveyed by postal questionnaire throughout the United
Kingdom (UK) between October 2015 and November 2016.
In England, Wales and Northern Ireland (NI) national,
population-based cancer registries were used to identify eli-
gible men, while in Scotland cancer registry verified hospital
activity data was used. The time period of 18-42months
was chosen as it reflects the point when initial treatment is
complete and side effects have begun to stabilise [16].
Survey
The survey asked men a range of socio-demographic
questions including marital status, employment status,
comorbidities and height and weight which were used to
calculate body mass index (see Additional file 1: Table S1
for categories used). Men were asked to indicate which of
the following treatment type(s) they received/were receiv-
ing: surgery, external-beam radiotherapy (EBRT), andro-
gen deprivation therapy (ADT), brachytherapy, systemic
(chemotherapy, abiraterone, enzalutamide), other treat-
ment and monitoring only (active surveillance and watch-
ful waiting). To determine method of presentation men
were asked how they were diagnosed with prostate cancer
and invited to tick all options that applied to them and/or
provide text comments (Additional file 2). Using both the
tick box responses and free-text comments men were
assigned to one of four groups:
1. PSA-detected: Men ticked that they had no
symptoms and either asked for or were offered a
PSA test either by their GP or as part of a private
health check;
2. Symptomatic: Men ticked that they attended their
GP with urinary or other symptoms, or mentioned
such symptoms in the free text box. These men
may or may not also have had a PSA test;
3. Other: Men ticked that they presented via another
method only;
4. Unknown: Men did not tick any box or did not
provide text comments that allowed assignment to
one of the previous three categories.
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The 26-item Expanded Prostate cancer Index Com-
posite (EPIC-26) [22] was used to assess health-related
functional outcomes. Similar to previous studies [12, 23],
reported prevalence experiencing specific problems was
based upon the proportion of men reporting moderate/
big problems (or equivalents such as poor/very poor) to
individual questions. Based upon the EPIC-26 scoring
instructions [24] the questions were divided up into five
domains (urinary incontinence, urinary irritation/ob-
struction, bowel function, sexual function, and vitality/
hormonal function), with summary scores for each
domain calculated by averaging standardised scores
assigned to responses to each question. All domains are
scored out of a total of 100, with a lower score repre-
senting more problems/poorer functioning.
Age, nation of residence and deprivation quintile
(based on area of residence at time of diagnosis) were
extracted from national cancer registries. Stage and
Gleason score at diagnosis were also provided by cancer
registries as measures of disease severity. Stage was
based upon the TNM classification, while Gleason score
was categorised as 2-6 (slow growing cancer), 7 (inter-
mediate risk of aggressive cancer) and 8-10 (cancer more
likely to spread rapidly).
Statistical analysis
As a result of variation in item completeness between
PSA-detected and symptomatic men (Additional file 1:
Table S1) all missing data items, except for method of
presentation, were imputed in order to reduce any bias
that may result from only including cases with complete
data [25, 26]. Multiple imputation with chained equa-
tions [27, 28] was utilised with all socio-demographic,
clinical characteristics, and EPIC-26 outcomes included.
A secondary analysis including complete cases only (i.e.
those men for whom all data items were complete) was
also conducted.
The characteristics of symptomatic and PSA-detected
men were compared using multivariable binary logistic
regression with age at diagnosis, nation, deprivation,
ethnicity, employment status, marital status, number of
co-morbidities, body mass index, stage at diagnosis,
Gleason score at diagnosis, and treatment type included
in the model.
Mean functional outcome scores for symptomatic and
PSA-detected men were initially compared using two
way ANOVA, with method of presentation, a second
characteristic (either age, stage, Gleason score or treat-
ment type) and an interaction term between the two
included. Multivariable log-linear regression with robust
standard errors was utilised to adjust for different case
mix between the two groups, with mean score ratios re-
ported. Age at diagnosis, nation, deprivation quintile of
residence, ethnicity, employment status, marital status,
number of co-morbidities, body mass index, stage at
diagnosis, Gleason score at diagnosis and treatment type
were included in the models for each outcome. Given
clinical interest in patients with particular clinical
characteristics and possible interaction identified by the
two-way ANOVA between method of presentation and
these characteristics, further sub group analysis was
conducted. Respondents were stratified by age, stage,
Gleason score and treatment types, with the multivariable
analysis also run for each strata. The Bonferonni correc-
tion was applied in the assessment of statistical signifi-
cance given that comparisons were made across multiple
outcomes. All analysis was conducted using Stata v14.
Results
A total of 35,823 men responded to the survey, a response
rate of 60.8%. Of these 11,210 (31.3%) were PSA-detected,
21,378 (59.7%) were symptomatic and 9.0% presented via
an alternative method (e.g. referral from urologist, emer-
gency admission to hospital) or with an unknown method
of presentation. Age, stage, Gleason score and treatment
type by presentation method are presented in Table 1, with
additional socio-demographic characteristics presented in
Additional file 1: Table S2. The distribution of all socio-
demographic and clinical characteristics included in these
tables varied significantly (all p < 0.001) by method of pres-
entation. The 3235 men who presented with an alterna-
tive/unknown method of presentation were subsequently
excluded leaving 32,588 PSA-detected/symptomatic pros-
tate cancer survivors available for analysis.
Method of presentation
Prostate cancer survivors aged 65-74 were more likely
than those aged under 55 to be PSA-detected (Adjusted
odds ratio (AOR): 0.83, 95% confidence interval (CI):
0.72-0.95), while compared to men diagnosed at stage I/
II, men diagnosed at stage III (AOR: 1.20, 95% CI: 1.12-
1.28) or stage IV (AOR: 2.03, 95% CI: 1.82-2.27) were
more likely to have been symptomatic. Compared to
those with Gleason score 2-6, men with a Gleason score
of 8-10 were more likely to present symptomatically
(AOR: 1.12, 95% CI: 1.03-1.22), while men with a score
of 7 were less likely to have presented symptomatically
(AOR: 0.86, 95% CI: 0.80-0.92). Men receiving brachy-
therapy (AOR: 0.77, 95% CI: 0.70-0.85) were more likely
to have been PSA-detected, while men receiving ADT
(AOR: 1.22, 95% CI: 1.14-1.30) or systemic treatment
(AOR: 1.64, 95% CI: 1.43-1.89) were more likely to have
been symptomatic (Table 2).
Unadjusted post-treatment outcomes (EPIC-26)
The proportion of PSA-detected men reporting moder-
ate/big problems for each EPIC-26 question was signifi-
cantly lower than for symptomatic men (p < 0.001), with
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the exception of problems with bloody stools, possibly
due to the low reported frequency of this outcome
(Fig. 1, Additional file 1: Table S3). Consequently mean
outcome scores for each EPIC-26 domain were higher
for PSA-detected men than symptomatic men (urinary
incontinence: 84.0 vs 80.1; urinary irritation: 87.3 vs
82.5; bowel problems: 90.0 vs 86.6; sexual problems: 29.3
vs 23.1; vitality/hormonal problems: 83.6 vs 76.8; all p <
0.001), indicating that problems were reported less
frequently (100 = no problems) by PSA-detected men.
This relationship was present for all subgroups of patients
defined by age, stage at diagnosis, Gleason score at diag-
nosis and treatment type (Additional file 1: Table S4).
Case-mix adjusted post-treatment outcomes by method
of presentation
After case-mix adjustment for clinical and socio-
demographic characteristics, all functional outcome
scores for symptomatic men were significantly lower
than for PSA-detected men (all p < 0.001). The great-
est relative difference was for sexual function, where
the mean sexual function score was 10.0% lower
(absolute difference in scores approximately 2.5 points)
among symptomatic men (Adjusted mean ratio (AMR):
0.90, 95% CI: 0.88-0.92). The smallest relative difference
was for bowel function which was on average 2.3% lower
(absolute difference in scores approximately 2.0 points)
among symptomatic men (AMR: 0.97, 95% CI: 0.97-0.98)
(Table 3).
This pattern was also present for those aged over and
under 75 and for stage I/II, stage III and stage IV pa-
tients (all p < 0.001), with the exception of no significant
difference in urinary incontinence or bowel function
between symptomatic and PSA-detected stage IV pa-
tients. Outcomes for prostate cancer survivors with
Gleason scores 2-6, 7 and 8-10 were also poorer among
those who presented symptomatically with the exception
of bowel function among those with Gleason score 8-10.
Among men receiving surgery, EBRT, ADT or monitor-
ing only, functional outcomes were also consistently
poorer among symptomatic men (Table 3).
Similar results were found in the complete case ana-
lysis, with the exception of no significant difference in
sexual function between symptomatic and PSA-detected







PSA-detected (n = 11,210) Symptomatic (n = 21,378) Other (n = 1821) Unknown (n = 1414)
Age at diagnosis
< 54 3.9% 4.0% 3.7% 5.7% 3.5%
55-64 23.8% 24.4% 23.7% 26.1% 17.5%
65-74 47.4% 48.9% 47.0% 46.1% 44.7%
75+ 24.9% 22.7% 25.6% 22.1% 34.4%
Stage
I/II 64.0% 71.2% 60.1% 65.3% 64.4%
III 23.3% 22.0% 24.3% 20.7% 21.6%
IV 12.7% 6.7% 15.6% 14.0% 14.0%
Gleason score
2-6 29.0% 31.1% 27.7% 29.5% 30.8%
7 47.3% 51.4% 45.3% 48.1% 45.0%
8-10 23.7% 17.5% 27.0% 22.3% 24.2%
Treatment type a
Any surgery 30.0% 31.9% 28.9% 31.8% 28.9%
Any EBRT 38.9% 37.5% 40.4% 35.6% 32.5%
Any brachytherapy 8.6% 10.7% 7.6% 7.7% 9.2%
Any ADT 43.0% 37.0% 46.6% 42.3% 37.6%
Any systemic 5.0% 2.5% 6.2% 5.7% 4.9%
Any other 14.0% 15.0% 13.3% 12.4% 18.5%
Monitoring only 16.8% 18.1% 15.9% 17.3% 20.2%
Notes
EBRT External Beam Radiotherapy, ADT Androgen Deprivation Therapy, Systemic - Chemotherapy/Abiraterone/Enzalutamide
Additional respondent characteristics are available in Additional file 1: Table S2
a Men may have more than one type of treatment
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men aged over 75, with stage III/IV disease or in receipt of
surgery. This is likely due to the reduction in statistical power
as the adjusted mean ratio is similar to that in the main
analysis using imputed data (Additional file 1: Table S5).
Discussion
This large UK wide population based study of over 35,800
prostate cancer survivors has enabled robust investigation
of variations in functional outcomes by presentation
method. We found that almost one third of survey re-
sponders reported presenting via a PSA test without ex-
periencing any symptoms prior to diagnosis. Urinary,
bowel, sexual and hormone-related problems are known
to vary among prostate cancer patients depending upon
treatment type [12–16]. To date, however, there has been
limited investigation of whether these problems vary by
method of presentation. We found that PSA-detected pa-
tients reported fewer urinary, bowel, sexual and hormone-
related problems after treatment for their cancer and that
these differences were independent of socio-demographic
and clinical factors including treatment.
Uniquely with this large dataset we have also been able
to investigate these patterns further by examining particu-
lar patient subgroups including age, stage, Gleason score
and treatments received. Within each patient subgroup
poorer outcomes were consistently reported by symptom-
atic men compared to those who were PSA-detected.
Differences between symptomatic and PSA-detected
men are not limited to functional issues. Drummond
et al. highlighted greater levels of depression, anxiety
and stress among symptomatic men independent of
treatment type and stage [17]. Similar to our study,
Table 2 Age, stage, Gleason score and treatment received for PSA-detected compared to symptomatic prostate cancer survivors#






Adjusted odds ratio (95% CI) of
being symptomatic compared to
PSA-detected b
(n = 32,588)
All respondents (n = 32,588) 34.4% 65.6% –
Age at diagnosis
< 54 36.3% 63.7% 1.00
55-64 35.0% 65.0% 0.92 (0.81-1.05)
65-74 35.3% 64.7% 0.83 (0.72-0.95)*
75+ 31.8% 68.2% 0.87 (0.75-1.01)
Stage
I/II 38.3% 61.7% 1.00
III 32.2% 67.8% 1.20 (1.12-1.28)**
IV 18.5% 81.5% 2.03 (1.82-2.27)**
Gleason score
2-6 37.0% 63.0% 1.00
7 37.3% 62.7% 0.86 (0.80-0.92)**
8-10 25.4% 74.6% 1.12 (1.03-1.22)*
Treatment type c
Any surgery 36.7% 63.3% 1.05 (0.98-1.13)
Any EBRT 32.7% 67.3% 1.04 (0.98-1.11)
Any brachytherapy 42.4% 57.6% 0.77 (0.70-0.85)**
Any ADT 29.4% 70.6% 1.22 (1.14-1.30)**
Any systemic 17.7% 82.3% 1.64 (1.43-1.89)**
Any other 37.1% 62.9% 1.00 (0.92-1.09)
Monitoring only 37.4% 62.6% 1.05 (0.96-1.16)
Notes
EBRT External Beam Radiotherapy, ADT Androgen Deprivation Therapy, Systemic - Chemotherapy/Abiraterone/Enzalutamide # Alive 18-42 months after diagnosis,
CI: Confidence interval
* p < 0.05, ** p < 0.001
a Denominator excludes other and missing method of presentation
b Determined using multivariable logistic regression adjusted for other variables in the table plus nation, deprivation, number of comorbidities, BMI, ethnicity,
marital status and employment status. An odds ratio greater than 1 represents a greater odds than the baseline (i.e. first) group of being symptomatic compared
to PSA-detected
c Men may have more than one type of treatment. Odds ratios for treatment type have a reference category of not receiving that treatment type (i.e. No surgery,
No EBRT etc.)
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Fig. 1 Proportion of PSA-detected and symptomatic prostate cancer survivors# reporting moderate/severe* urinary, bowel and sexual problems,
feeling depressed and lack of energy, measured using unadjusted individual items from the EPIC-26 questionnaire. Notes: See Additional file 1:
Table S3 for further responses to individual questions, including confidence intervals and the results of statistical tests comparing patient groups.
Error bars represent the 95% confidence intervals around each proportion. # Alive 18-42 months after diagnosis; * or equivalents such as
poor/very poor







Adjusted mean ratio (95% CI) – symptomatic vs. PSA-detected a
Urinary incontinence Urinary irritation/ obstruction Bowel function Sexual function Vitality/ hormonal function
All respondents 32,588 0.96 (0.96-0.97)** 0.95 (0.95-0.96)** 0.97 (0.97-0.98)** 0.90 (0.88-0.92)** 0.96 (0.96-0.96)**
Age group
Under 75 24,566 0.96 (0.95-0.96)** 0.95 (0.95-0.96)** 0.97 (0.97-0.98)** 0.91 (0.89-0.93)** 0.96 (0.95-0.96)**
75 and over 8017 0.97 (0.95-0.98)** 0.96 (0.95-0.97)** 0.98 (0.97-0.99)** 0.91 (0.86-0.96)* 0.96 (0.95-0.98)**
Stage
I/II 17,818 0.96 (0.95-0.96)** 0.95 (0.95-0.96)** 0.97 (0.97-0.98)** 0.91 (0.88-0.93)** 0.96 (0.96-0.97)**
III 6643 0.97 (0.95-0.98)** 0.96 (0.95-0.97)** 0.98 (0.97-0.99)** 0.88 (0.83-0.94)** 0.96 (0.94-0.97)**
IV 3535 0.98 (0.96-1.00) 0.96 (0.95-0.98)** 0.99 (0.97-1.01) 0.86 (0.76-0.96)* 0.95 (0.92-0.97)**
Gleason score
2-6 8083 0.97 (0.96-0.98)** 0.95 (0.94-0.96)** 0.97 (0.97-0.98)** 0.93 (0.90-0.96)** 0.97 (0.96-0.97)**
7 12,917 0.95 (0.95-0.96)** 0.96 (0.95-0.96)** 0.97 (0.96-0.98)** 0.88 (0.85-0.91)** 0.88 (0.85-0.91)**
8-10 6077 0.97 (0.96-0.99)* 0.96 (0.95-0.97)** 0.99 (0.98-1.00) 0.87 (0.80-0.93)* 0.95 (0.93-0.96)**
Treatment type b
Any surgery 9710 0.97 (0.96-0.99)* 0.96 (0.96-0.97)** 0.97 (0.97-0.98)** 0.93 (0.89-0.97)* 0.96 (0.96-0.97)**
Any EBRT 12,780 0.96 (0.95-0.97)** 0.96 (0.95-0.96)** 0.97 (0.97-0.98)** 0.84 (0.80-0.87)** 0.95 (0.94-0.96)**
Any ADT 14,016 0.96 (0.95-0.97)** 0.96 (0.95-0.96)** 0.98 (0.97-0.98)** 0.86 (0.82-0.90)** 0.95 (0.94-0.96)**
Monitoring only 5378 0.95 (0.94-0.96)** 0.94 (0.93-0.94)** 0.97 (0.97-0.98)** 0.91 (0.88-0.94)** 0.97 (0.96-0.98)**
Notes
CI Confidence Interval, EBRT External Beam Radiotherapy, ADT Androgen Deprivation Therapy
*p < 0.05, **p < 0.001 after Bonferroni correction for multiple comparisons
a Determined using multivariable log-linear model adjusted for other variables in the table plus nation, deprivation, number of comorbidities, BMI, ethnicity,
marital status and employment status. An adjusted mean score of less than one can be interpreted to mean that symptomatic patients have poorer functionality
than PSA-detected patients
b Men may have more than one type of treatment
c Alive 18-42 months after diagnosis
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Drummond et al. also reported higher levels of incontin-
ence, impotence, bowel problems and fatigue among
symptomatic men [17], although, unlike our study, these
findings were not adjusted for treatment, stage and Glea-
son score at diagnosis.
Similar to other studies [17–19], PSA-detected men
from this study had earlier stage of disease compared to
symptomatically diagnosed men and were more likely to
have brachytherapy than men who presented symptomat-
ically, while symptomatic men were more likely to be
treated with ADT. Given that adjusting for these factors
did not eliminate differences in outcomes between differ-
ent presentation methods, other factors are likely to be
responsible for the better quality of life of PSA-detected
men. A possible explanation is that PSA-detected men
have better overall health and are less likely to have urin-
ary, bowel and sexual problems prior to their prostate
cancer diagnosis. PSA-detected men might also have been
better supported already and have received (or been able
to access) interventions to ameliorate functional problems.
Further research is warranted to determine whether the
differences reported here are due to better underlying
physical and mental health of PSA-detected men or other
systematic differences between the groups.
These findings suggest that men with symptomatic pres-
entation need more follow up care for urinary, bowel and
vitality/hormonal problems, regardless of whether these
problems are due to treatment, background morbidity or
lingering effects of presenting symptoms. Further research
is required to assess whether investigation and treatment
of symptoms prior to cancer patient management has a
beneficial effect on functional outcomes. Importantly,
these findings suggest method of presentation is a key
factor in prostate cancer outcome studies and is an
important covariate when comparing outcomes between
patient groups with differing proportions of men who are
symptomatic and PSA-detected.
Strengths and limitations
Although this large population-based study had a good
response rate and consisted of clinical data and patient
reported outcomes, some limitations exist. Symptoms and
treatments were self-reported and subjective rather than
based upon clinical assessment or cancer-registration data.
Also, while we have adjusted for clinical and socio-
demographic factors, adjustments for treatment and back-
ground morbidity may be limited due to lack of information
on treatment intensity (e.g. duration, frequency, radiation
fraction, and ADT type), severity of co-morbidities or
general health of patients before prostate cancer diagnosis.
Additionally, the use of area based deprivation measures
and employment status may not fully reflect each individ-
ual’s socio-economic status, thereby not fully capturing their
health literacy and ability to negotiate health services.
It is also worth highlighting that while differences
reported in this study are statistically significant this
does not necessarily mean that they represent clinically
significant or meaningful differences. Skolarus et al. [29]
suggested clinically meaningful important differences
(MID) for the EPIC-26 scores for comparisons at an
individual level. In the event that these MIDs can be
applied to populations, they suggest that only the differ-
ences in urinary irritation/obstruction and hormonal
function for all patient subgroups, and differences for
bowel function among younger men (aged under 64)
may qualify as being clinically relevant. It is also import-
ant to note that conclusions about variations between
patient groups may not necessarily reflect the experience
of every individual patient.
Conclusion
Prostate cancer survivors who present symptomatically
have poorer urinary, bowel, sexual and vitality/hormonal
function than those who were PSA-detected. Differences
are not explained by the socio-demographic and clinical
factors collected in the study, with this pattern observed
for survivors of different age, diagnosed at early and late
stage and in receipt of different treatment types. Health
professionals should be aware that men presenting
symptomatically report more functional difficulties after
prostate cancer treatment, although this may be a result
of poorer general health prior to diagnosis. Furthermore,
method of presentation should be considered as a covar-
iate in future prostate cancer outcome studies as quality
of life varies by this characteristic which may thus par-
tially explain differences in outcomes between patient
groups that have different proportions of symptomatic
prostate cancer.
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